-
1

1	Title: Maternal over-the-counter analgesics use during pregnancy and adverse
2	perinatal outcomes: Cohort study of 151,141 singleton pregnancies

3

Authors: ¹Aikaterini ZAFEIRI, MSci, Ms, ²Edwin A. RAJA, PhD, ³Rod T. MITCHELL,
 MBChB, PhD, ⁴David C. HAY, PhD, ⁵Sohinee BHATTACHARYA, MBBS, PhD, ¹Paul

6 A. FOWLER, FRSB, PhD

⁷ ¹Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition,

8 University of Aberdeen, Aberdeen, United Kingdom, ²Medical Statistics Team,

9 Institute of Applied Health Sciences, School of Medicine, Medical Sciences and

10 Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ³MRC Centre for

11 Reproductive Health, The Queen's Medical Research Institute, University of

12 Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4JT, UK, ⁴MRC Centre for

13 Regenerative Medicine, 5 Little France Drive, Edinburgh, UK, ⁵Aberdeen Centre for

14 Women's Health Research, Institute of Applied Health Sciences, School of Medicine,

15 Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom,

16 Corresponding Author: Aikaterini Zafeiri, Institute of Medical Sciences, School of

17 Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United

- 18 Kingdom, cell phone number: (+44)7713837285, email: r01az17@abdn.ac.uk
- 19 **Running Title:** Maternal over-the-counter analgesia and offspring outcomes

20 Abstract

21 OBJECTIVES

- 22 To identify any associations between in utero exposure to five over-the-counter (non-
- 23 prescription) analgesics (paracetamol, ibuprofen, aspirin, diclofenac, naproxen) and
- 24 adverse neonatal outcomes.
- 25 DESIGN
- 26 Retrospective cohort study using the Aberdeen Maternity and Neonatal Databank.
- 27 PARTICIPANTS
- 151,141 singleton pregnancies between 1985 and 2015.
- 29 MAIN OUTCOME MEASURES

Premature delivery (<37 weeks), stillbirth, neonatal death, birthweight, standardised
birthweight score, neonatal unit admission, APGAR score at 1 and 5 minutes, neural
tube and amniotic band defects, gastroschisis and, in males, cryptorchidism, and
hypospadias.

34 RESULTS

83.7% of women taking over-the-counter analgesics reported first trimester use

36 when specifically asked about use at their first antenatal clinic visit. Pregnancies

37 exposed to at least one of the five analgesics were significantly independently

- associated with increased risks for premature delivery <37 weeks (aOR=1.50,
- 39 95%CI 1.43-1.58), stillbirth (aOR=1.33, 95%CI 1.15-1.54), neonatal death
- 40 (aOR=1.56, 95%CI 1.27-1.93), birthweight <2,500g (aOR=1.28, 95%CI 1.20-1.37),
- birthweight >4,000g (aOR=1.09, 95%CI 1.05-1.13), admission to neonatal unit

3

(aOR=1.57, 95%Cl 1.51-1.64), APGAR score <7 at 1 minute (aOR=1.18, 95%Cl
1.13-1.23) and 5 minutes (aOR=1.48, 95%Cl 1.35-1.62), neural tube defects
(aOR=1.64, 95%Cl 1.08-2.47) and hypospadias (aOR=1.27, 95%Cl 1.05-1.54 males
only). The overall prevalence of over-the-counter analgesics use during pregnancy
was 29.1%, however it rapidly increased over the 30-year study period, to include
over 60% of women in the last seven years of the study. This makes our findings
highly relevant to the wider pregnant population.

49 CONCLUSIONS

50 Over-the-counter (non-prescription) analgesics consumption during pregnancy was 51 associated with a substantially higher risk for adverse perinatal health outcomes in 52 the offspring. The use of paracetamol in combination with other non-steroidal anti-53 inflammatory drugs conferred the highest risk. The increased risks of adverse 54 neonatal outcomes associated with non-prescribed, over-the-counter, analgesics use 55 during pregnancy indicate that healthcare guidance for pregnant women regarding 56 analgesic use need urgent updating.

57

Funding Biotechnology and Biological Sciences Research council (BBSRC) funding
under the EASTBIO doctoral training programme (grant number 1942576) to AZ and
EU Horizon 2020 project FREIA (Grant Number 825100) to PAF. RTM is supported
by MRC Centre for Reproductive Health Grant MR/N022556/1.

62 Key words acetaminophen, aspirin, diclofenac, ibuprofen, *in utero* exposure,

naproxen, offspring outcomes, over-the-counter analgesics, offspring outcomes,

64 paracetamol, pregnancy

4

66 Introduction

Globally 23-85% of women use one or more types of prescribed medications during 67 pregnancy ^{1,2}. A similarly high proportion of expectant mothers self-medicate using 68 non-prescription, "over-the-counter" (OTC) medicines ^{3,4} and use during pregnancy 69 is becoming increasingly prevalent, especially in Western countries ⁵. While some 70 71 analgesics e.g. paracetamol are considered safe to consume throughout pregnancy, use of non-steroidal anti-inflammatory drugs (NSAIDs) is not recommended in 72 pregnancy unless on the advice of a medical specialist and should be avoided 73 beyond gestational week 30 because of the risk of premature closure of the ductus 74 arteriosus. However, current evidence is largely conflicting regarding the safety of 75 gestational analgesic use both for the pregnancy and offspring health ⁶. Several 76 studies have reported increased risks for multiple adverse outcomes including 77 hypospadias, cryptorchidism, amniotic band defects and neural tube defects 7-11, 78 whilst others have not found significant associations ^{12–17}. Taken overall, this has led 79 to significant concern that postnatal health is adversely affected by maternal 80 analgesic use during pregnancy ¹⁸. 81

The use of small cohorts in the current epidemiological studies makes it difficult to 82 draw firm conclusions and definite recommendations^{12,17,19,20}. There are other 83 84 aspects of analgesic use that have to be taken into account. Firstly, due to their abundance, it is not always feasible to determine exact consumption rates and 85 dosage. Secondly, even though the mechanisms of action for most of these 86 compounds is not fully understood, most over-the-counter analgesics can diffuse 87 through the placenta and reach the developing fetus ²¹. Thirdly, maternal 88 pharmacokinetics during pregnancy are altered and there are limited pregnancy 89 safety data for these compounds. 90

5

91 Given the diversity in study population, methodology, sample size and findings in the published studies, we conclude that more extensive data from larger cohorts are 92 essential in order to understand the risks over-the-counter analgesic use during 93 pregnancy pose to neonatal health and function. Here we address many limitations 94 of previous studies by analysing one of the largest cohorts, widest range of health 95 data and, pregnancy use of five over-the-counter analgesics consumed in 96 97 combination or separately. We report on the prevalence of maternal consumption of five different over-the-counter analgesics during pregnancy and their associations 98 99 with offspring neonatal outcomes using a large cohort of 151,141 singleton pregnancies spanning three decades of population-based data from a single 100 maternity hospital serving the entire population of Aberdeenshire in the North East of 101 102 Scotland.

6

103 Materials and Methods

This retrospective cohort study utilised data collected in the Aberdeen Maternity and 104 Neonatal Databank (AMND) in Aberdeen, UK on 151,141 pregnancies over a 30 105 vear period (1985-2015). Details about AMND have been previously published ²². 106 Data were collected from medical notes of women retrospectively after delivery. 107 108 Women were specifically asked about their use of over-the-counter (nonprescription) analgesics at their first antenatal clinic. Data were entered by dedicated 109 coding staff into a computerised database. Data validity was ensured via checking 110 completeness of data entry against NHS (UK National Health Service) returns 111 monthly and constant data cleaning and validation against case notes reported 112 113 guarterly by the Data Management team to the AMND Steering Committee. A research protocol was submitted and approved by the AMND Steering Committee 114 before data extraction. Approval was received on 6 June 2018. The dataset was fully 115 116 anonymised, therefore there was no requirement for NHS ethics committee approval. The main analysis considered consumption during pregnancy of at least one out of 117 five different analgesics: paracetamol (no; yes), ibuprofen (no; yes), naproxen (no; 118 yes), diclofenac (no; yes) or aspirin (no; yes) as the exposure group against no 119 analgesic consumption as the unexposed group. Then, three sub-group analyses 120 121 against the control group were performed using only paracetamol, only diclofenac, or at least one analgesic from aspirin/naproxen/ibuprofen as exposure groups, 122 excluding pregnancies exposed to multiple analgesics at the same time. As 98.3% of 123 124 pregnancies using diclofenac were between 2005 and 2015, diclofenac sub-group analysis only considered pregnancies during that time frame in order to rule out any 125 temporal effect. 126

127	The offspring outcomes compared between control and exposed groups were:
128	gestation at delivery (preterm <37 gestation weeks, term \geq 37 gestation weeks),
129	pregnancy outcome (livebirth, stillbirth, neonatal death), baby weight (low birth
130	weight (LBW) \leq 2,499 g, high birth weight (HBW) \geq 4,000 g, normal birth weight
131	(NBW) 2,500g-3,999 g), standardised birthweight score was considered as a
132	continuous variable as previously described by Campbell and colleagues ²³ , baby
133	admission to neonatal unit (no; yes), APGAR score at one and five minutes (<7, \geq 7),
134	cryptorchidism (no; yes) (ICD-10 code Q53), neural tube defects (no; yes) (ICD-10
135	code Q00-07), amniotic band defects (no; yes) (ICD-10 codes Q70-74), hypospadias
136	(no; yes) (ICD-10 code Q54), gastroschisis (no; yes) (ICD-10 code Q79.3). A
137	composite outcome (presence of at least one congenital anomaly (no; yes)) was
138	created using the variables neural tube defects, amniotic band defects, and
139	gastroschisis and, in males, cryptorchidism and hypospadias.
140	The baseline characteristics compared between exposed and unexposed
140 141	The baseline characteristics compared between exposed and unexposed pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004,
141	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004,
141 142	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous
141 142 143	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9
141 142 143 144	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9 kg/m ² , underweight <18.5 kg/m ² , overweight 25-29.9 kg/m ² , obese <30 kg/m ²),
141 142 143 144 145	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9 kg/m ² , underweight <18.5 kg/m ² , overweight 25-29.9 kg/m ² , obese <30 kg/m ²), maternal first antenatal visit (1st, 2nd, 3rd trimester), maternal smoking status (non-
141 142 143 144 145 146	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9 kg/m ² , underweight <18.5 kg/m ² , overweight 25-29.9 kg/m ² , obese <30 kg/m ²), maternal first antenatal visit (1st, 2nd, 3rd trimester), maternal smoking status (non-smoker, smoker, ex-smoker), Scottish Index of Multiple Deprivation (SIMD) decile (1-
141 142 143 144 145 146 147	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9 kg/m ² , underweight <18.5 kg/m ² , overweight 25-29.9 kg/m ² , obese <30 kg/m ²), maternal first antenatal visit (1st, 2nd, 3rd trimester), maternal smoking status (non-smoker, smoker, ex-smoker), Scottish Index of Multiple Deprivation (SIMD) decile (1-6, 7-10, decreasing deprivation with increasing score), maternal hypertensive
141 142 143 144 145 146 147 148	pregnancies were (reference category first): year of delivery (1985-1994, 1995-2004, 2005-2015), maternal age at delivery (20-25, <20, 26-35, >35 years), previous pregnancy (no; yes), maternal body mass index (BMI) (normal weight 18.5-24.9 kg/m ² , underweight <18.5 kg/m ² , overweight 25-29.9 kg/m ² , obese <30 kg/m ²), maternal first antenatal visit (1st, 2nd, 3rd trimester), maternal smoking status (non-smoker, smoker, ex-smoker), Scottish Index of Multiple Deprivation (SIMD) decile (1-6, 7-10, decreasing deprivation with increasing score), maternal hypertensive disorders (no disorder, gestational hypertension, preeclampsia, eclampsia), maternal

8

labour (no; yes), baby presentation at delivery (occiput anterior, occiput posterior),
baby sex (female; male).

154

155 Statistical Analysis

Baseline characteristics were compared between exposed and unexposed 156 pregnancies to any analgesic using χ^2 test for categorical variables and t-test for 157 normally distributed continuous variables as appropriate. Relationships between 158 exposures and outcomes were examined by binary logistic regression for binary 159 outcome variables, multinomial logistic regression for nominal categorical outcome 160 variables, and multiple linear regression for continuous variables. The strength of 161 association was reported as odds ratios (ORs) with 95% confidence intervals (CI). 162 The socio-demographic characteristics that were likely to confound our exposure-to-163 outcome path were identified using a directed acyclic graph (DAG) (Figure S1)²⁴. 164 Factors that were associated with consumption of over-the-counter analgesics during 165 pregnancy at 10% level of significance and deemed clinically relevant, were included 166 in the model as confounders. All outcomes were adjusted for year of delivery, 167 maternal age at delivery, SIMD and maternal first antenatal visit. In addition to these 168 confounders, individual outcomes were adjusted for relevant cofactors. Gestation at 169 delivery and pregnancy outcome were both additionally adjusted for maternal 170 hypertensive disorders and antepartum haemorrhage. Weight of the baby, neonatal 171 unit admission, cryptorchidism, neural tube defects, amniotic band defects, 172 hypospadias and gastroschisis variables were also adjusted for gestation at delivery. 173 APGAR score at one and five minutes were adjusted for type of delivery. A p-value 174 of less than 0.05 was considered statistically significant. All statistical analyses were 175

- carried out using IBM SPSS Statistics version 25.0 (Released 2017. IBM SPSS 176
- Statistics for Windows, Armonk, NY: IBM Corp.). R version 3.6.2 was used to 177
- generate Figure 2. 178

10

179 **Results**

83.7% of women taking over-the-counter analgesics reported first trimester use 180 when specifically asked about use at their first antenatal clinic. Overall, from the total 181 151,141 pregnancies across 30 years in 107,143 (70.9%) pregnancies, no over-the-182 counter analgesic consumption was reported. At least one over-the-counter 183 184 analgesic was consumed in 43,998 (29.1%) pregnancies, whereas paracetamol use alone was reported in 24,099 (18.4%) pregnancies. Diclofenac use was observed in 185 20.0% of pregnancies in the 10-year period when diclofenac was available over-the-186 counter (without prescription). Finally, at least one out of three analgesics (naproxen, 187 ibuprofen, aspirin) was consumed in 762 (0.7%) pregnancies (Figure 1). 188 189 Prevalence of use for all five analgesics increased dramatically over the 30-year study period (1985-2015) (Figure 2). Percentage of pregnancies with consumption of 190 at least one analgesic increased from 1.8% in 1985 to 70.6% in 2015. Paracetamol 191 was consumed in 1.3% of pregnancies in 1985 and it continuously increased 192 reaching 42.2% in 2015. Naproxen, ibuprofen or aspirin consumption during 193 pregnancy was less prevalent (Figure 2A), however it also increased during the 30-194 year study period, starting at 0.5% in 1985 and reaching 1.9% in 2015 (Figure 2B). 195 Diclofenac was consumed in very few pregnancies between 1985 (<0.01%) and 196 197 2005 (0.2%). Percentage of consumption, however, dramatically increased during the next decade following deregulation of diclofenac, reaching 25.0% in just one year 198 (2006) and 45.6% of all pregnancies in 2015. 199

Table 1 compares the baseline characteristics between the unexposed group of pregnancies where no analgesic was consumed and each of the exposure groups. In most, but not all, comparisons across all four analyses, there was a statistically

11

203	significant difference (p<0.001) for most variables. In the paracetamol sub-group
204	analysis, baby presentation at delivery (p=0.525) and sex of the baby (p=0.861) were
205	not significantly different between the groups. In the analysis considering
206	consumption of at least one analgesic from aspirin/naproxen/ibuprofen, again the
207	variables for baby presentation at delivery (p=0.093) and sex of the baby (p=0.732),
208	together with maternal smoking status (p=0.132) and maternal antepartum
209	haemorrhage (p=0.434) were not statistically different compared to the unexposed
210	group. All variables were statistically different between unexposed and exposed
211	groups for the main analysis and diclofenac sub-group analysis.
212	Table 2 summarises the comparison of neonatal outcomes between the unexposed
213	group (no analgesic at all) and the exposed groups of at least one analgesic, only
214	paracetamol and at least one out of aspirin/naproxen/ibuprofen. Comparison of
215	outcomes for the diclofenac sub-group analysis is shown in Table 3.

216

217 All analgesics and neonatal outcomes

218 As shown in Table 2, compared to unexposed pregnancies in which women did not use any analgesic, pregnancies with consumption of at least one analgesic 219 (paracetamol, diclofenac, aspirin, naproxen, ibuprofen) were independently 220 associated with significantly higher odds for premature delivery (aOR=1.50, 95%CI 221 1.43-1.58), stillbirth (aOR=1.33, 95%CI1.15-1.54), LBW (aOR=1.28, 95%CI 1.20-222 1.37), HBW (aOR=1.09, 95%CI 1.05-1.13), baby admission to neonatal unit 223 (aOR=1.57, 95%CI 1.51-1.64), APGAR score <7 at five minutes (aOR=1.48, 95%CI 224 1.35-1.62), neural tube defects (aOR=1.64, 95%CI 1.08-2.47) and hypospadias 225 226 (aOR=1.27, 95%CI 1.05-1.54) in adjusted analyses. Significantly decreased odds for

12

227	APGAR score <7 at one minute were found in the crude analysis (cOR=0.96, 95%CI
228	0.92-0.99), however when adjusted for year of delivery, maternal age at delivery,
229	SIMD, first gestational booking and type of delivery, the significance changed
230	direction showing significantly increased odds (aOR=1.18, 95%CI 1.13-1.23). A
231	significantly lower standardised birthweight score (aOR=0.046. 95%CI 0.032-0.059)
232	was found for the exposure group compared to no analgesic at all. Cryptorchidism
233	(aOR=0.92, 95%CI 0.77-1.11), amniotic band defects (aOR=1.02, 95%CI 0.71-1.47),
234	gastroschisis (aOR=1.10, 95%CI 0.56-2.20) and the composite outcome variable
235	(aOR=1.12, 95%CI 0.99-1.26), were all associated with increased odds in the
236	exposure group compared to not exposed, however the association was not
237	significant in the adjusted model. There was no significant association between
238	neonatal death and exposure to at least one analgesic in the crude analysis
239	(cOR=1.19, 95%CI 0.99-1.42), however there were significantly higher odds of
240	neonatal death in the adjusted analysis (aOR=1.56, 95%CI 1.27-1.93) in the
241	exposed group compared to control.

242

243 Paracetamol and neonatal outcomes

In the sub-group analysis considering only paracetamol consumption during
pregnancy as our exposure group, most of the associations reported in the main
analysis remained significant with the same direction of significance (Table 2). The
differences were: maternal paracetamol consumption during pregnancy was
associated with significantly decreased odds for offspring HBW (cOR=0.94, 95%CI
0.90-0.99) in the crude analysis however significance was lost in the adjusted model
(aOR=0.98, 95%CI 0.93-1.02), and there were no significant associations in the

13

adjusted models for neural tube defects (aOR=1.21, 95%CI 0.71-2.06) and 251 hypospadias (aOR=1.07, 95%CI 0.84-1.37). 252

253

Aspirin/naproxen/ibuprofen and neonatal outcomes 254

255 Consumption of at least one analgesic from aspirin, naproxen or ibuprofen during pregnancy was compared against the same control group of pregnancies where no 256 analgesic was used (Table 2). Again, when comparing associations between groups 257 in this sub-group analysis and main analysis, fewer outcome variants showed similar 258 significance pattern. The only shared significant associations were for increased 259 odds for premature delivery (aOR=1.42, 95%CI 1.08-1.86), stillbirth (aOR=2.34, 260 95%CI 1.29-4.25) and baby admission to neonatal unit (aOR=1.54, 95%CI 1.22-261 1.94) in the adjusted regression analyses. 262

263

Diclofenac and neonatal outcomes 264

265 In the sub-group analysis of pregnancies coinciding with non-prescription, over-thecounter, availability of diclofenac (years 2005-2015) were considered, and outcomes 266 compared between the diclofenac group and no analgesic consumption group (Table 267 3). Compared to the main analysis, diclofenac consumption during pregnancy was 268 not significantly associated with premature delivery (aOR=1.10, 95%CI 0.99-1.22), 269 neonatal death (aOR=1.26, 95%CI 0.73-2.15) and APGAR score <7 in one minute 270 (aOR=0.93, 95%CI 0.83-1.04) in the adjusted models. Associations with APGAR 271 score <7 in five minutes (aOR=0.94, 95%CI 0.72-1.23), cryptorchidism (aOR=1.05, 272 95%CI 0.78-1.42), amniotic band defects (aOR=0.81, 95%CI 0.41-1.58) and 273 gastroschisis (aOR=2.93, 95%CI 0.97-8.88) were no longer significant in both crude 274

14

- and adjusted analyses. Maternal consumption of diclofenac was independently
- associated with a significant decrease in stillbirth (aOR=0.59, 95%CI 0.41-0.87). It is
- also interesting to note that diclofenac was the only sub-group analysis agreeing with
- the main analysis (exposure to at least one analgesic) on the significance of
- exposure association with increased incidence of neural tube defects (aOR=3.62,
- 280 95%CI 1.95-6.74) and hypospadias (aOR=1.49, 95%CI 1.09-2.03) compared to
- unexposed pregnancies in adjusted models.

15

283 Discussion

284 Main Findings

285 Consumption of paracetamol, ibuprofen, aspirin and naproxen during pregnancy, either in combination or separately, was significantly associated with increased 286 premature delivery, stillbirth, neonatal death, LBW, abnormal standardised 287 birthweight score and more frequent admission to neonatal unit. Consumption of 288 paracetamol alone was further associated with higher odds for APGAR score <7 at 289 290 one and five minutes both in crude and adjusted analyses. There was a dramatic increase in the frequency of over-the-counter (non-prescription) analgesic use in 291 pregnancies between 1985 and 2015, reaching 70.5% of women in the final decade 292 293 of our study. This means that our findings are applicable far beyond the percentage (between 14% and 38%)²⁵ of pregnant women with underlying health deficits related 294 to the adverse outcomes we report here. 295

296

Diclofenac use increased steeply from 2005 (Figure 2A), which reflects the change in 297 Scottish legislation, leading to diclofenac becoming available without prescription in 298 that year. Diclofenac use was associated with fewer adverse outcomes but showed 299 increased risk of neural tube defects and hypospadias in male neonates. 300 Furthermore, and surprisingly, exposure to diclofenac only was associated with 301 significant decrease in the incidence of stillbirth. The reasons for such differences 302 between the changes in neonatal outcomes following diclofenac consumption 303 compared with those following use of the other NSAIDS are not clear. The proportion 304 of women using diclofenac, especially in the last 7 years of our study makes it highly 305 unlikely to be due to an underlying maternal condition and/or other compounds used 306

16

in combination (e.g. prescriptions) by women taking diclofenac. It is possible that the 307 drug could act directly on fetal development then this difference could also be due to 308 structural and/or mechanistic differences of the compound compared to the other 309 drugs. However, not enough is known about the specific mechanisms of action of the 310 different analgesics studied to conclude further. Overall, comparing our main 311 analysis with all three sub-analyses, it is evident that the most significant differences 312 313 were observed when paracetamol was taken with at least one other analgesic. This is mostly due to the high number of pregnancies where paracetamol was used, 314 315 comprising almost 55% of the exposed cases in the main analysis.

316

317 Strengths and Limitations

A major strength of the present study is the large cohort of 151,141 pregnancies over 318 a 30-year study period from 1985 until 2015, using a robust data source AMND. This 319 is one of the largest cohorts used in studies examining the effects of analgesic use 320 during pregnancy. The dataset contains high quality and consistent data from the 321 geographically defined area of Aberdeen and surrounding district, in the North East 322 of Scotland, UK. In addition, as Aberdeen Maternity Hospital is the only maternity 323 hospital serving the area, over 95% of pregnancies in the area are included in the 324 dataset, considerably minimizing the risk for selection bias. We were able to analyse 325 maternal consumption data of the five most commonly used analgesics available 326 over-the-counter in the UK and most countries, which is not matched in the current 327 literature. The nature of our data allowed for the analysis of analgesics consumed 328 alone or in combination, unlike most existing studies, and this gives our study the 329 added strength of better reflecting real-life consumption patterns ^{26,27}. We were able 330

17

to adjust for important confounding factors, relevant to each analysed outcome.
Adjustment for maternal deprivation also allowed us to further account for potential
unmeasured factors that can influence maternal and neonatal health, which is a
major strength of our analysis compared to most studies.

A potential concern was that women were probably using analgesics to treat some 335 336 inherent medical condition which in turn could have been the mediating factor for adverse outcomes. However, since these medications are widely available without 337 prescription, this is unlikely to be a factor that affects the findings of this study. This 338 is especially the case during the "diclofenac analysis" covering 2005-2015, where 339 340 this study presents results on multiple neonatal outcomes for the given cohort. In this 341 way we offer a comprehensive approach to the exploration of associations with in utero analgesic exposure rather than only focusing on a single outcome of interest. 342 Our data were based on medical notes; however, over-the-counter consumption is 343 self-reported, and details on the timing, dosage, product type (single-ingredient vs 344 combination) and administration type were not available in the database. Complete 345 case analyses were performed ignoring pregnancies with missing data in the 346 covariates, however due to the low number of missing data there is little chance that 347 this might have affected the validity of our results. Compared to our cohort size, 348 349 there were, overall, very few cases of cryptorchidism, neural tube defects, amniotic band defects, hypospadias and gastroschisis, resulting in potentially underpowered 350 statistical analyses to detect a difference for these outcomes. Our study only 351 352 considered neonatal health outcomes and follow-up of the offspring was not available at this time. 353

18

355 Interpretation

Previous literature has considered fewer outcomes with fewer analgesic 356 combinations compared to our study. Consistent with our results, increased risk of 357 preterm birth and miscarriage has been associated with analgesic consumption 358 during pregnancy ^{28–31}, while others reported no associations with miscarriage, 359 stillbirth or preterm delivery ^{20,28,29,32}. Similarly, increased risk for offspring 360 cryptorchidism, hypospadias, neural tube defects, amniotic band defects and 361 gastroschisis have been shown by many studies 7-9,33-40, although, again, a lack of 362 associations with major birth defects have been reported ^{13–17,41,42}. Compared to our 363 analysis, all these studies used a smaller cohort, considered a shorter study time 364 and there was frequent disagreement with respect to the choices of adjusted 365 confounding factors. Another difference is that maternal questionnaires/interviews 366 were frequently the method of choice to evaluate maternal consumption. Some of 367 368 the studies reported increased risks for specific pregnancy trimesters which is something our study could not evaluate. Differences in study design and adjustment 369 for different confounders might also account for the disagreement of our results that 370 provide a more accurate assessment. Our study is one of the largest in terms of 371 cohort size, duration, number of analgesics and range of outcomes included which 372 might also contribute to differences compared to other studies. 373

The literature currently reports conflicting evidence, limiting our ability for definite decision-making. Over-the-counter analgesics are recommended to women by healthcare professionals in order to deal with pregnancy symptoms and other conditions. Policy-makers have taken a stand on the topic, either being reassuring about over-the-counter use during pregnancy or recommending caution when consumption is necessary ^{43–46}. Different compounds can affect the mother and the

19

fetus in a different way, and their combined use might worsen the risk for offspring ill
health. This study demonstrates the need for additional research, before the field can
be confidently directed towards one direction or the other.

Whether the associations we report result from flu, fever, rheumatological or 383 inflammatory conditions, and/or combination with other prescribed medications or 384 385 solely related to over-the-counter analgesics consumption is a matter of further research. Underlying health conditions could well influence the outcomes we see in 386 this study, however, as these could be very different conditions it is biologically 387 unlikely that they are responsible for the effects we observe here. Our study 388 demonstrates an association of maternal over-the-counter analgesic consumption 389 during pregnancy with adverse neonatal offspring outcomes. Future collaborative 390 approaches such as an individual patient data meta-analysis that includes follow-up 391 data on long-term outcomes during childhood and adulthood would significantly 392 393 inform decision making. Going forward, uncovering the mechanisms of action and off target effects will also provide a solid foundation for the development of pregnancy-394 safe compounds. Finally, the findings present here suggest that diclofenac is 395 associated with fewer changes in risk for the more frequent adverse outcomes 396 although it is associated more with rarer, but severe, negative outcomes, including 397 neural tube defects. Diclofenac may have a lower risk for the main adverse neonatal 398 outcomes reported for paracetamol. However, it should be noted that our study is not 399 designed to specifically test differences in level of risk between the analgesics 400 included. Therefore, it should be emphasised that this does not mean that the 401 authors are stating that diclofenac is preferable to paracetamol. 402

20

404 **Conclusions**

Pain control is currently a therapeutic priority during pregnancy. Our findings of
increased risk of adverse health outcomes for the offspring following at least first
trimester maternal use of readily available over-the-counter analgesics are crucial to
information for the management of pain during pregnancy.

409

410 Acknowledgements: N/A

411 **Disclosure of interests:** Professor David Hay is a founder, director and shareholder
412 in Stemnovate Limited. The remaining authors have no interests to disclose.

Contribution to Authorship: AZ, SB and PAF contributed to the conception, design and coordination of the research. EAR provided critical input in the design and planning of statistical analysis. AZ conducted the statistical analysis and prepared the manuscript, figures and tables. AZ, SB, PAF, RTM and DCH substantially contributed to the analysis and interpretation of the work. All authors contributed to tritical discussion of intellectual content, development and review/approval of the final manuscript version.

Funding: This work is supported by the Biotechnology and Biological Sciences
Research council (BBSRC) funding the lead author under the EASTBIO doctoral
training programme and to PAF, the EU Horizon 2020 project FREIA (Grant Number
825100). RTM is supported by MRC Centre for Reproductive Health Grant
MR/N022556/1. The funders had no role in study design, data collection, data
analysis, decision to publish, or manuscript preparation.

- 426 Ethics Statement: The AMND dataset used in this study was fully anonymised,
- 427 therefore there was no requirement for ethical approval. The North of Scotland
- 428 Research Ethics Service has devolved Caldicott approval to the Chair of the AMND
- 429 steering committee. Approval to access and analyse data was obtained from the
- 430 AMND steering Committee (AMND 004/2018).

22

432 **References**

- 433 1. Gendron M-P, Martin B, Oraichi D, Berard A. Health care providers' requests
- 434 to Teratogen Information Services on medication use during pregnancy and

435 lactation. *Eur J Clin Pharmacol*. 2009;65(5):523-531.

- 436 2. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S.
- 437 Medication use during pregnancy, with particular focus on prescription drugs:
- 438 1976-2008. *Am J Obstet Gynecol*. 2011;205(1):51.e1-51.e8.
- 439 3. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-
- 440 counter medications during pregnancy. *Am J Obstet Gynecol*.
- 441 2005;193(3):771-777.
- 442 4. Glover DD, Amonkar M, Rybeck BF, Tracy TS. Prescription, over-the-counter,
 443 and herbal medicine use in a rural, obstetric population. *Am J Obstet Gynecol*.
 444 2003;188(4):1039-1045.
- Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: A crosssectional, multinational web-based study. *BMJ Open*. 2014;4(2).
- Zafeiri A, Mitchell RT, Hay DC, Fowler PA. Over-the-counter analgesics during
 pregnancy: a comprehensive review of global prevalence and offspring safety.
 Hum Reprod Update. Published online October 29, 2020.
- 450 7. Lynberg MC, Khoury MJ, Lu X, Cocian T. Maternal flu, fever, and the risk of
- 451 neural tube defects: A population-based case-control study. *Am J Epidemiol*.
 452 1994;140(3):244-255.
- 453 8. Werler MM, Louik C, Mitchell AA. Epidemiologic analysis of maternal factors
 454 and amniotic band defects. *Birth Defects Res Part A Clin Mol Teratol.*

23

455 2003;67(1):68-72.

456	9.	Snijder CA, Kortenkamp A, Steegers EAP, et al. Intrauterine exposure to mild
457		analgesics during pregnancy and the occurrence of cryptorchidism and
458		hypospadia in the offspring: The Generation R Study. Hum Reprod.
459		2012;27(4):1191-1201.
460	10.	Lind JN, Tinker SC, Broussard CS, et al. Maternal medication and herbal use
461		and risk for hypospadias: Data from the National Birth Defects Prevention
462		Study, 1997-2007. Pharmacoepidemiol Drug Saf. 2013;22(7):783-793.
463	11.	Interrante JD, Ailes EC, Lind JN, et al. Risk comparison for prenatal use of
464		analgesics and selected birth defects, National Birth Defects Prevention Study
465		1997–2011. Ann Epidemiol. 2017;27(10):645-653.e2.
466	12.	Philippat C, Gorgis-Allemand L, Chevrier C, et al. Analgesics during pregnancy
466 467	12.	Philippat C, Gorgis-Allemand L, Chevrier C, et al. Analgesics during pregnancy and undescended testis. <i>Epidemiology</i> . 2011;22(5):747-749.
	12. 13.	
467		and undescended testis. <i>Epidemiology</i> . 2011;22(5):747-749.
467 468		and undescended testis. <i>Epidemiology</i> . 2011;22(5):747-749. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal
467 468 469		and undescended testis. <i>Epidemiology</i> . 2011;22(5):747-749. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. In:
467 468 469 470		and undescended testis. <i>Epidemiology</i> . 2011;22(5):747-749. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. In: <i>American Journal of Obstetrics and Gynecology</i> . Vol 206. Mosby Inc.;
467 468 469 470 471	13.	and undescended testis. <i>Epidemiology</i> . 2011;22(5):747-749. Hernandez RK, Werler MM, Romitti P, Sun L, Anderka M. Nonsteroidal antiinflammatory drug use among women and the risk of birth defects. In: <i>American Journal of Obstetrics and Gynecology</i> . Vol 206. Mosby Inc.; 2012:228.e1-228.e8.

476 2018;77:122-129.

475

477 16. van Gelder MMHJ, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-

early pregnancy: A prospective observational cohort study. Reprod Toxicol.

- inflammatory drugs during pregnancy and the risk of selected birth defects: A
 prospective cohort study. *PLoS One*. 2011;6(7).
- 480 17. Dathe K, Fietz AK, Pritchard LW, et al. No evidence of adverse pregnancy
- 481 outcome after exposure to ibuprofen in the first trimester Evaluation of the
- 482 national Embryotox cohort. *Reprod Toxicol*. 2018;79:32-38.
- 18. Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-
- 484 Associated Changes in Pharmacokinetics: A Systematic Review. Chappell LC,
- 485 ed. *PLoS Med.* 2016;13(11):e1002160.
- 486 19. McElhatton PR, Sullivan FM, Volans GN. Paracetamol overdose in pregnancy
- 487 analysis of the outcomes of 300 cases referred to the teratology information
- 488 service. *Reprod Toxicol*. 1997;11(1):85-94.
- 489 20. Kozer E, Costei AM, Boskovic R, Nulman I, Nikfar S, Koren G. Effects of
- 490 aspirin consumption during pregnancy on pregnancy outcomes: Meta-analysis.
- 491 Birth Defects Res Part B Dev Reprod Toxicol. 2003;68(1):70-84.
- 492 21. Nitsche JF, Patil AS, Langman LJ, et al. Transplacental Passage of
- Acetaminophen in Term Pregnancy. *Am J Perinatol.* 2017;34(6):541-543.
- 494 22. Ayorinde AA, Wilde K, Lemon J, Campbell D, Bhattacharya S. Data resource
- 495 profile: The Aberdeen Maternity and Neonatal Databank (AMND). Int J
- 496 *Epidemiol.* 2016;45(2):389-394.
- 497 23. Campbell D, Hall M, Lemon J, Carr-Hill R, Pritchard C, Samphier M. Clinical
- birthweight standards for a total population in the 1980s. *BJOG An Int J Obstet Gynaecol.* 1993;100(5):436-445.
- 500 24. Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, Ellison GT. Robust

501	causal inference using directed acyclic graphs: The R package "dagitty." Int J
502	Epidemiol. 2016;45(6):1887-1894.

- 503 25. Royal College of Obstetricians and Gynaecologists. RCOG review clarifies
- 504 pain relief options for women during pregnancy and breastfeeding. Published
- 505 2018. https://www.rcog.org.uk/en/news/new-rcog-review-clarifies-pain-relief-
- 506 options-for-women-during-pregnancy-and-breastfeeding/
- 507 26. Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and
- associations of analgesic use in Germany. *BMC Pharmacol Toxicol*.
- 509 2015;16(1).
- 510 27. Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in
- 511 France over the last 10 years and comparison of patterns across Europe. *Br J* 512 *Clin Pharmacol.* 2018;84(6):1324-1334.
- 513 28. Rebordosa C, Kogevinas M, Bech BH, Sørensen HT, Olsen J. Use of
- acetaminophen during pregnancy and risk of adverse pregnancy outcomes. *Int J Epidemiol*. 2009;38(3):706-714.
- 516 29. Nielsen GL, Sørensen HT, Larsen H, Pedersen L. Risk of adverse birth
- 517 outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory
- drugs: Population based observational study and case-control study. *Br Med J*.
- 519 2001;322(7281):266-270.
- 30. Czeizel AE, Dudá I, Puhó E. Short-term paracetamol therapy during pregnancy
 and a lower rate of preterm birth. *Paediatr Perinat Epidemiol*. 2005;19(2):106111.
- 523 31. Li Z, Ren A, Liu J, et al. Maternal flu or fever, medication use, and neural tube

524		defects: A population-based case-control study in northern China. Birth
525		Defects Res Part A - Clin Mol Teratol. 2007;79(4):295-300.
526	32.	Pastore LM, Hertz-Picciotto I, Beaumont JJ. Risk of stillbirth from medications,
527		illnesses and medical procedures. Paediatr Perinat Epidemiol. 1999;13(4):421-
528		430.
529	33.	Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin
530		consumption during the first trimester of pregnancy and congenital anomalies:
531		A meta-analysis. Am J Obstet Gynecol. 2002;187(6):1623-1630.
532	34.	Kristensen DM, Hass U, Lesn L, et al. Intrauterine exposure to mild analgesics
533		is a risk factor for development of male reproductive disorders in human and
534		rat. <i>Hum Reprod</i> . 2011;26(1):235-244.
535	35.	Jensen MS, Rebordosa C, Thulstrup AM, et al. Maternal use of
536		acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk
537		of cryptorchidism. <i>Epidemiology</i> . 2010;21(6):779-785.
538	36.	Correy JF, Newman NM, Collins JA, Burrows EA, Burrows RF, Curran JT. Use
539		of prescription drugs in the first trimester and congenital malformations. Aust N
540		<i>Z J Obs Gynaecol.</i> 1991;31(4):340-344.
541	37.	Lind DV, Main KM, Kyhl HB, et al. Maternal use of mild analgesics during
542		pregnancy associated with reduced anogenital distance in sons: A cohort
543		study of 1027 mother-child pairs. Hum Reprod. 2017;32(1):223-231.
544	38.	Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in
545		relation to gastroschisis. Teratology. 1992;45(4):361-367.
546	39.	Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJR. Maternal medications

27

547	and environmenta	exposures as	risk factors for	gastroschisis.	Teratology.
-----	------------------	--------------	------------------	----------------	-------------

- 548 1996;54(2):84-92.
- 40. M. Werler M, Sheehan JE, Mitchell AA. Maternal medication use and risks of
- 550 gastroschisis and small intestinal atresia. *Am J Epidemiol*. 2002;155(1):26-31.
- 41. Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S.
- 552 ASPIRIN AND CONGENITAL MALFORMATIONS. Lancet.
- 553 1976;307(7974):1373-1375.
- 42. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever,
- and medication use as risk factors for neural tube defects. *Teratology*.

556 1998;57(1):1-7.

43. Mosley II JF, Smith LL, Dezan MD. An overview of upcoming changes in

558 pregnancy and lactation labeling information. *Pharm Pract (Granada)*.

559 2015;13(2):605.

- 560 44. SMFM (Society for Maternal-Fetal Medicine Publications Committee). Prenatal
 561 acetaminophen use and outcomes in children. *Am J Obstet Gynecol*.
- 562 2017;216(3):B14-B15.
- 45. Bisson DL, Newell SD, Laxton C. Antenatal and Postnatal Analgesia: Scientific
 Impact Paper No. 59. *BJOG An Int J Obstet Gynaecol*. 2018;(59).
- 46. RCOG. RCOG review clarifies pain relief options for women during pregnancy
- and breastfeeding. Published 2018. https://www.rcog.org.uk/en/news/new-
- 567 rcog-review-clarifies-pain-relief-options-for-women-during-pregnancy-and-

568 breastfeeding/

 Table 1.
 Comparison of baseline characteristics between exposed (use of analgesics) and unexposed (no analgesic use) groups of pregnancies (P values <0.05 shown in bold).</td>

Baseline Characteristics	No analgesic (n=107,143) n (%)	At least one analgesic (n=43,998) n (%)	P value†	Paracetamol (n=24,099) n (%)	P value†	Ibuprofen/ Aspirin/ Naproxen (n=762) n (%)	P value†	No analgesic 2005-2015 (n=20,544) n (%)	Diclofenac 2005-2015 (n=10,291) n (%)	P value‡
Year of delivery				•		•		•	•	-
1985-1994	50,152 (46.8)	5,737 (13.0)	<0.001	5,390 (22.4)	<0.001	213 (28.0)	<0.001	n/a	n/a	<0.001
1995-2004	36,447 (34.0)	7,263 (16.5)		6,571 (27.3)		321 (42.1)	_	n/a	n/a	
2005-2015 /	20,544 (19.2)	30,998 (70.5)		12,138 (50.4)		228 (29.9)		n/a	n/a	
2005-2009 *	n/a	n/a		n/a		n/a		11,105 (54.1)	4,021 (39.1)	
2010-2015 *	n/a	n/a		n/a		n/a		9,439 (45.9)	6,270 (60.9)	
Maternal age at de	livery									
Younger than 20	9,236 (8.6)	3,834 (8.7)	<0.001	2,936 (12.2)	<0.001	34 (4.5)	<0.001	1,286 (6.3)	311 (3.0)	<0.001
20-25	24,249 (22.6)	8,700 (19.8)		5,932 (24.6)		113 (14.8)		3,436 (16.7)	1,152 (11.2)	
26-35	63,499 (59.3)	25,367 (57.7)		12,896 (53.5)		464 (60.9)		12,664 (61.1)	6,628 (64.4)	
Older than 35	10,159 (9.5)	6,097 (13.9)		2,335 (9.7)		151 (19.8)		3,158 (15.4)	2,200 (21.4)	
Previous Parity										
Nulliparity (0)	48,684 (45.4)	23,353 (53.1)	<0.001	12,510 (51.9)	<0.001	300 (39.4)	0.004	8,336 (40.6)	5 <i>,</i> 004 (48.6)	<0.001
Multiparity (1-11)	58,457 (54.6)	20,639 (46.9)		11,587 (48.1)		462 (60.6)		12,206 (59.4)	5,284 (51.4)	
Missing	2 (<0.1) §	6 (<0.1) §		2 (<0.1)§		0 (0.0) §		2 (<0.1)§	3 (<0.1) §	
Maternal BMI								•		
Underweight (<18.5)	1,998 (2.4)	869 (2.2)	<0.001	545 (2.6)	<0.001	10 (1.5)	0.007	492 (2.7)	174 (1.9)	<0.001
Normal weight (18.5-24.9)	50,127 (60.8)	18,958 (48.8)		10,486 (50.5)		361 (55.)		10,239 (55.2)	4,671 (50.0)	-
Overweight (25.0-29.9)	20,500 (24.9)	10,960 (28.2)		5,733 (27.6)		192 (29.5)		4,930 (26.6)	2,630 (28.1)	
Obese (< 30.0)	9,773 (11.9)	8,046 (20.7)		3,995 (19.2)		88 (13.5)		2,881 (15.5)	1,871 (20.0)	
Missing data	24,745 (23.1) §	5,165 (11.7) §		3,340 (13.9) §		111 (14.6) §	-	2,002 (9.7) §	945 (9.2) §	

Gestation weeks at	earliest antenata	l visit								
1 st Trimester	69,896 (65.4)	36,789 (83.7)	<0.001	19,075 (79.2)	<0.001	569 (75.0)	<0.001	18,155 (88.4)	9,185 (89.4)	0.036
2 nd Trimester	29,269 (27.4)	5,791 (13.2)		4,117 (17.1)		166 (21.9)		1,770 (8.6)	829 (8.1)	
3 rd Trimester	7,741 (7.2)	1,376 (3.1)		890 (3.7)		24 (3.2)		605 (2.9)	264 (2.6)	
Missing	237 (0.2) §	42 (0.1) §		17 (0.1) §		3 (0.4) §		14 (0.1) §	13 (0.1) §	
Maternal smoking	Status						·	÷	·	·
Unknown	6,505 (6.1) §	819 (1.9) §	<0.001	500 (2.1) §	<0.001	32 (4.2) §	0.132	448 (2.2) §	155 (1.5) §	<0.001
Ex-smoker	5,952 (5.6)	3,363 (7.6)		1,923 (8.1)		35 (4.8)		1,427 (7.1)	660 (6.5)	
Non-smoker	70,319 (69.9)	31,421 (72.8)		15,755 (66.8)		534 (73.2)		15,525 (77.3)	8,368 (82.6)	
Smoker	24,367 (24.2)	8,395 (19.4)	5,921 (25.1)		161 (22.2)		3,144 (15.6)	1,108 (10.9)		
Maternal SIMD Dec	ile						·	·		·
Least Deprived	65,227 (61.8)	25,192 (57.9)	<0.001	12,807 (53.8)	<0.001	501 (66.3)	0.012	12,806 (62.9)	6,714 (66.1)	<0.001
(7-10)	40.224 (20.2)	40.200 (42.4)		11.017 (16.2)	-	255 (22 7)	_	7.564 (27.4)		-
Most Deprived (1-6)	40,321 (38.2)	18,289 (42.1)		11,017 (46.2)		255 (33.7)		7,564 (37.1)	3,442 (33.9)	
Missing	1,595 (1.5) §	517 (1.2) §		275 (1.1) §		6 (0.8) §		174 (0.8) §	135 (1.3) §	-
Maternal hyperten	sive disorders									
None	91,276 (85.2)	35,529 (80.8)	<0.001	18,635 (77.3)	<0.001	636 (83.5)	0.001	18,851 (91.8)	9,273 (90.1)	<0.001
Gestational	13,029 (12.2)	5,501 (12.5)		3,584 (14.9)		88 (11.5)		1,165 (5.7)	690 (6.7)	
Hypertension										
Preeclampsia	2,780 (2.6)	2,941 (6.7)		1,861 (7.7)		38 (5.0)		523 (2.5)	324 (3.1)	
Eclampsia	58 (0.1)	27 (0.1)		19 (0.1)		0 (0.0)		5 (<0.1)	4 (<0.1)	
Maternal antepartu	im haemorrhage						·	÷	·	·
No haemorrhage	97,527 (91.0)	37,673 (85.6)	<0.001	20,306 (84.3)	<0.001	684 (89.8)	0.434	18,549 (90.3)	9,244 (89.8)	< 0.001
Abruption	697 (0.7)	468 (1.1)		221 (0.9)		8 (1.0)		103 (0.5)	106 (1.0)	
Placenta previa	308 (0.3)	368 (0.8)		152 (0.6)		2 (0.3)		23 (0.1)	114 (1.1)	
Unspecified	8,611 (8.0)	5,489 (12.5)		3,420 (14.2)		68 (8.9)	1	1,869 (9.1)	827 (8.0)	
Type of labour										
Elective Caesarean	5,967 (5.6)	6,925 (15.7)	<0.001	1,384 (5.7)	<0.001	67 (8.8)	<0.001	616 (3.0)	3,843 (37.3)	<0.001
Section										
Induced	24,120 (22.5)	16,276 (37.0)		10,067 (41.8)		228 (29.9)		3,895 (19.0)	1,998 (19.4)	
Spontaneous	77,056 (71.9)	20,797 (47.3)		12,648 (52.5)		467 (61.3)		16,033 (78.0)	4,450 (43.2)	

Type of delivery										
Spontaneous vaginal delivery (SVD)	75,027 (70.1)	19,287 (43.8)	<0.001	15,983 (66.3)	<0.001	496 (65.2)	0.003	16,398 (79.8)	1,403 (13.6)	<0.001
Instrumental	15,409 (14.4)	8,107 (18.4)		4,043 (16.8)		120 (15.8)		2,546 (12.4)	1,927 (18.7)	
Caesarean Section	15,566 (14.5)	16,351 (37.2)		3,879 (16.1)		141 (18.5)		1,509 (7.3)	6,937 (67.4)	
Other	1,096 (1.0)	247 (0.6)		191 (0.8)		4 (0.5)		89 (0.4)	24 (0.2)	
Missing	45 (<0.1) §	6 (<0.1) §		3 (<0.1) §		1 (0.1) §		2 (<0.1) §	0 (0.0) §	
Analgesia during la	bour									
No	105,176 (98.2)	36,117 (82.1)	<0.001	20,974 (87.0)	<0.001	729 (95.7)	<0.001	19,915 (96.9)	8,235 (80.0)	<0.001
Yes	1,967 (1.8)	7,881 (17.9)		3,125 (13.0)		33 (4.3)		629 (3.1)	2,056 (20.0)	
Baby presentation	at delivery									
Occiput anterior	11,571 (10.8)	8,152 (18.6)	<0.001	2,636 (11.0)	0.525	68 (8.9)	0.093	1,401 (6.8)	2,967 (28.9)	<0.001
Occiput posterior	95,352 (89.2)	35,745 (81.4)		21,409 (89.0)		694 (91.1)		19,100 (93.2)	7,306 (71.1)	
Missing	220 (0.2) §	101 (0.2) §		54 (0.2) §		0 (0.0) §		43 (0.2) §	18 (0.2) §	
Sex of baby										
Female	52,265 (48.8)	21,139 (48.0)	0.010	11,739 (48.7)	0.861	367 (48.2)	0.732	10,124 (49.3)	4,907 (47.7)	0.008
Male	54,866 (51.2)	22,852 (51.9)		12,354 (51.3)		395 (51.8)		10,417 (50.7)	5,384 (52.3)	
Missing	12 (<0.1)§	7 (<0.1) §		6 (<0.1) §		0 (0.0) §		3 (<0.1) §	0 (0.0) §	

570 n/a, not applicable; n, number of pregnancies

571 *Only applicable to Diclofenac 2005-2015 analysis

†p value in comparison to the first ("No analgesic") column

‡p value in comparison to "No analgesic 2005-2015" control column

§Percentage of missing data on total, not included in the analysis

 Table 2. Regression analysis of offspring outcomes between control (no analgesic) and groups exposed to at least one analgesic, only paracetamol, and at least one from ibuprofen, aspirin, naproxen.
 31

	No analgesic	At least one			Paracetamol			Ibu/Asp/Na		
Outcomes	(n=107,143)	analgesic			(n=24,099)			pr		
	n (%)	(n=43,998)	Crude	Adjusted	n (%)	Crude	Adjusted	(n=762)	Crude	Adjusted
		n (%)	OR (CI 95%)	OR (95% CI)		OR (95% CI)	OR (95% CI)	n (%)	OR (95% CI)	OR (95% CI)
	t delivery (weeks)	1		1		Г				
>=37	100,879 (94.2)	39,838 (90.5)	1.00	1.00	21,589 (89.6)	1.00	1.00	697 (91.5)	1.00	1.00
<37	6,264 (5.8)	4,160 (9.5)	1.68 (1.61-1.75)	1.50 (1.43-1.58) ^a	2,510 (10.4)	1.87 (1.78-1.97)	1.56 (1.48-1.65) ^a	65 (8.5)	1.50 (1.16-1.94)	1.42 (1.08-1.86) ^a
Pregnancy of			1		1	1	1			
Livebirth	105,949 (98.9)	43,407 (98.7)	1.00	1.00	23,704 (98.4)	1.00	1.00	747 (98.0)	1.00	1.00
Stillbirth	803 (0.7)	405 (0.9)	1.23 (1.09-1.39)	1.33 (1.15-1.54) ^a	275 (1.1)	1.53 (1.33-1.76)	1.52 (1.30-1.77) ^a	13 (1.7)	2.30 (1.32-3.99)	2.34 (1.29-4.25) a
Neonatal	373 (0.3)	182 (0.4)	1.19 (0.99-1.42)	1.56 (1.27-1.93) ^a	117 (0.5)	1.40 (1.14-1.73)	1.56 (1.24-1.96) ^a	2 (0.3)	0.76 (0.19-3.06)	0.93 (0.23-3.74) ª
Death										
Missing	18 (<0.1)	4 (<0.1)	n/a	n/a	3 (<0.1)	n/a	n/a	0 (0.0)	n/a	n/a
Weight of b	aby (grams)					• ·				
NBW	87,966 (82.1)	34,555 (78.6)	1.00	1.00	19,163 (79.5)	1.00	1.00	605 (79.5)	1.00	1.00
LBW	5,910 (5.5)	3,571 (8.1)	1.54 (1.47-1.61)	1.28 (1.20-1.37) ^b	2,213 (9.2)	1.72 (1.63-1.81)	1.60 (1.51-1.69) b	59 (7.7)	1.45 (1.11-1.90)	1.29 (0.91-1.83) b
HBW	13,233 (12.4)	5,863 (13.3)	1.13 (1.09-1.17)	1.09 (1.05-1.13) ^b	2,720 (11.3)	0.94 (0.90-0.99)	0.98 (0.93-1.02) b	97 (12.7)	1.07 (0.86-1.32)	0.99 (0.80-1.24) b
Missing	34 (<0.1)	9 (<0.1)	n/a	n/a	3 (<0.1)	n/a	n/a	1 (0.1)	n/a	n/a
Standardise	d Birthweight Sco	re	•				•		•	
Mean (SD)	0.001 (0.003)	-0.002 (0.065)	0.03 (0.02-0.04)	0.046 (0.032-	0.001 (0.991)	-0.04 (-0.058	-0.014 (-0.029-	0.046	0.045 (-0.029-	0.049 (-0.025-
				0.059) c		0.029)	0.001) c	(0.038)	0.119)	0.123) °
Admitted to	o neonatal unit	•		·	·			-		<u>.</u>
No	62,378 (58.2)	32,391 (73.6)	1.00	1.00	16,342 (67.8)	1.00	1.00	480 (63.0)	1.00	1.00
Yes	11,011 (10.3)	7,448 (16.9)	1.30 (1.26-1.35)	1.57 (1.51-1.64) b	3,956 (16.4)	1.37 (1.32-1.43)	1.45 (1.38-1.53) ^b	117 (15.4)	1.38 (1.13-1.69)	1.54 (1.22-1.94) b
Missing	33,754 (31.5)	4,159 (9.5)	n/a	n/a	3,801 (15.8)	n/a	n/a	762 (21.7)	n/a	n/a
APGAR scor	re at 1 min					1 -				
Normal	92,217 (86.1)	38,224 (86.9)	1.00	1.00	20,593 (85.5)	1.00	1.00	659 (86.5)	1.00	1.00
<7	14,335 (13.4)	5,674 (12.9)	0.96 (0.92-0.99)	1.18 (1.13-1.23) d	3,437(14.3)	1.07 (1.03-1.12)	1.23 (1.18-1.28) d	101 (13.3)	0.99 (0.80-1.22)	1.07 (0.86-1.32) d
Missing	591 (0.6)	100 (0.2)		n/a	69 (0.3)	n/a	n/a	2 (0.3)	n/a	n/a
APGAR scor	re at 5 min		ł			1				
Normal	104,292 (97.3)	42,730 (97.1)	1.00	1.00	23,334 (96.8)	1.00	1.00	738 (96.9)	1.00	1.00
<7	2,216 (2.1)	1,163 (2.6)	1.28 (1.19-1.38)	1.48 (1.35-1.62) d	690 (2.9)	1.39 (1.28-1.52)	1.53 (1.40-1.68) d	21 (2.8)	1.34 (0.87-2.07)	1.52 (0.97-2.36) d
Missing	635 (0.6)	105 (0.2)	n/a	n/a	75 (0.3)	n/a	n/a	3 (0.4)	n/a	n/a
Cryptorchid	lism (only males in	cluded)	· ·	<u> </u>						
No	54,509 (99.3)	22,616 (99.0)	1.00	1.00	12,247 (99.1)	1.00	1.00	394 (99.4)	1.00	1.00
Yes	357 (0.7)	236 (1.0)	1.59 (1.35-1.88)	0.92 (0.77-1.11) ^b	107 (0.9)	1.33 (1.07-1.66)	0.87 (0.69-1.09) b	1 (0.3)	0.39 (0.05-2.77)	0.28 (0.04-1.98) b
Neural Tub		· · ·	· · · ·	<u> </u>	· · ·	,	. ,	. <i></i>	· · · · ·	· · · · /

No	107,093 (99.9)	43,928 (99.8)	1.00	1.00	24,077 (99.9)	1.00	1.00	762 (100)	1.00	1.00
Yes	50 (0.1)	70 (0.2)	3.41 (2.37-4.91)	1.64 (1.08-2.47) ^b	22 (0.1)	1.96 (1.19-3.23)	1.21 (0.71-2.06) b	0 (0.0)	n/a	n/a
Amniotic	Band Defects									
No	107,053 (99.9)	43,936 (99.9)	1.00	1.00	24,070 (99.9)	1.00	1.00	760 (99.7)	1.00	1.00
Yes	90 (0.1)	62 (0.1)	1.68 (1.21-2.32)	1.02 (0.71-1.47) ^b	29 (0.1)	1.43 (0.94-2.18)	0.98 (0.63-1.52) ^b	2 (0.3)	3.13 (0.77-12.73)	2.29 (0.56-9.37) ^b
Hypospad	lias (only males inclu	ded)								
No	54,607 (99.5)	22,600 (98.9)	1.00	1.00	12,258 (99.2)	1.00	1.00	390 (98.7)	1.00	1.00
Yes	259 (0.3)	252 (1.1)	2.35 (1.98-2.80)	1.27 (1.05-1.54) ^b	96 (0.8)	1.65 (1.31-2.09)	1.07 (0.84-1.37) ^b	5 (1.3)	2.70 (1.11-6.59)	1.91 (0.78-4.68) ^b
Gastrosch	isis									
No	107,120 (99.9)	43,979 (99.9)	1.00	1.00	24,089 (99.9)	1.00	1.00	762(100)	1.00	1.00
Yes	23 (0.1)	19 (0.1)	2.01 (1.10-3.70)	1.10 (0.56-2.20) b	10 (0.1)	1.93 (0.92-4.06)	0.99 (0.45-2.21) ^b	0 (0.0)	n/a	n/a
At least o	ne outcome*				•			•		
No	106,367 (99.3%)	43,363 (98.6%)	1.00	1.00	23,835 (98.9%)	1.00	1.00	754 (99.0%)	1.00	1.00
Yes	776 (0.7%)	635 (1.4%)	2.01 (1.81-2.23)	1.12 (0.99-1.26) b	264 (1.1%)	1.52 (1.32-1.75)	0.97 (0.84-1.13) ^b	8 (1.0%)	1.45 (0.72-2.93)	1.11 (0.55-2.23) ^b

575 n/a, not applicable; n, number of pregnancies

³ Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, maternal hypertensive disorders, maternal antepartum

577 haemorrhage

^b Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, gestation at delivery

⁵⁷⁹ ^c Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking

^dAdjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, type of delivery

581 *Including cryptorchidism, neural tube defects, amniotic band defects, hypospadias, gastroschisis

Table 3. Sub-group regression analysis between control pregnancies and exposed to diclofenac.

(n=20,544) n (%) ry (weeks) 407 (94.5%) 37 (5.5%) e 393 (99.3%) (0.5%)	2005-2015 (n=10,291) n (%) 9,640 (93.7%) 651 (6.3%) 10,227 (99.4%) 39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%) 17 (0.2%)	Crude OR (CI 95%) 1.00 1.15 (1.04, 1.27) 1.00 0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00 1.12 (1.03, 1.21)	Adjusted OR (CI 95%) 1.00 1.10 (0.99, 1.22) a 1.00 0.59 (0.41, 0.87) a 1.26 (0.73, 2.15) a 1.26 (0.73, 2.15) a 1.20 1.22 (1.07, 1.40) b 1.21 (1.13, 1.29) b 0.167 (0.141, 0.193) c 1.00 1.46 (1.35, 1.58) b 1.00 0.93 (0.83, 1.04) d
ry (weeks) 407 (94.5%) 37 (5.5%) e 393 (99.3%) 6 (0.5%) 0.2%) ams) 369 (82.1%) 07 (13.2%) 1.0%) weight Score 039 (0.959) tal unit 224 (88.7%) 75 (10.6%) 6 (0.7%) nin 709 (91.1%) 58 (8.1%)	n (%) 9,640 (93.7%) 651 (6.3%) 10,227 (99.4%) 39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	OR (CI 95%) 1.00 1.15 (1.04, 1.27) 1.00 0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	OR (CI 95%) 1.00 1.10 (0.99, 1.22) a 1.00 0.59 (0.41, 0.87) a 1.26 (0.73, 2.15) a 1.00 1.22 (1.07, 1.40) b 1.21 (1.13, 1.29) b 0.167 (0.141, 0.193) c 1.00 1.46 (1.35, 1.58) b 1.00 1.00
407 (94.5%) 37 (5.5%) e 393 (99.3%) (0.5%) (0.2%) 369 (82.1%) (4.7%) 07 (13.2%) 0.0%) weight Score 139 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	9,640 (93.7%) 651 (6.3%) 10,227 (99.4%) 39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00 1.15 (1.04, 1.27) 1.00 0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.00 1.10 (0.99, 1.22) a 1.00 0.59 (0.41, 0.87) a 1.26 (0.73, 2.15) a 1.00 1.22 (1.07, 1.40) b 1.21 (1.13, 1.29) b 0.167 (0.141, 0.193) c 1.00 1.46 (1.35, 1.58) b 1.00
407 (94.5%) 37 (5.5%) e 393 (99.3%) (0.5%) (0.2%) 369 (82.1%) (4.7%) 07 (13.2%) 0.0%) weight Score 139 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	651 (6.3%) 10,227 (99.4%) 39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.15 (1.04, 1.27) 1.00 0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.10 (0.99, 1.22) ^a 1.00 0.59 (0.41, 0.87) ^a 1.26 (0.73, 2.15) ^a 1.00 1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 1.00 1.46 (1.35, 1.58) ^b 1.00
37 (5.5%) e 393 (99.3%) 5 (0.5%) 0.2%) ams) 369 (82.1%) (4.7%) 07 (13.2%) 0.0%) weight Score 039 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	651 (6.3%) 10,227 (99.4%) 39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.15 (1.04, 1.27) 1.00 0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.10 (0.99, 1.22) ^a 1.00 0.59 (0.41, 0.87) ^a 1.26 (0.73, 2.15) ^a 1.00 1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 1.00 1.46 (1.35, 1.58) ^b 1.00
e 393 (99.3%) (0.5%) (0.2%) ams) 369 (82.1%) (4.7%) 07 (13.2%) 0.0%) weight Score 139 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	10,227 (99.4%) 39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00 0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.00 0.59 (0.41, 0.87) a 1.26 (0.73, 2.15) a 1.00 1.22 (1.07, 1.40) b 1.21 (1.13, 1.29) b 0.167 (0.141, 0.193) c 1.00 1.46 (1.35, 1.58) b 1.00
393 (99.3%) (0.5%) (0.2%) ams) 369 (82.1%) (4.7%) 07 (13.2%) 07 (13.2%) 00%) weight Score 39 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	0.59 (0.41, 0.87) a 1.26 (0.73, 2.15) a 1.00 1.22 (1.07, 1.40) b 1.21 (1.13, 1.29) b 0.167 (0.141, 0.193) c 1.00 1.46 (1.35, 1.58) b 1.00
6 (0.5%) (0.2%) 6 (0.2%) 6 (0.2%) 6 (0.2%) 6 (0.2%) 6 (0.2%) 7 (13.2%) 7 (13.2%)	39 (0.4%) 25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	0.67 (0.47, 0.96) 1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	0.59 (0.41, 0.87) a 1.26 (0.73, 2.15) a 1.00 1.22 (1.07, 1.40) b 1.21 (1.13, 1.29) b 0.167 (0.141, 0.193) c 1.00 1.46 (1.35, 1.58) b 1.00
0.2%) ams) 369 (82.1%) (4.7%) 07 (13.2%) 1.0%) weight Score 039 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	25 (0.2%) 8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.42 (0.85, 2.38) 1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.26 (0.73, 2.15) ^a 1.00 1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 0.167 (0.141, 0.193) ^c 1.00 1.46 (1.35, 1.58) ^b 1.00
ams) 369 (82.1%) (4.7%) 07 (13.2%) 0.0%) weight Score 139 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	8,116 (78.9%) 572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00 1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.00 1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 0.167 (0.141, 0.193) ^c 1.00 1.46 (1.35, 1.58) ^b 1.00
369 (82.1%) (4.7%) 07 (13.2%) 0.07) usight Score 39 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 0.167 (0.141, 0.193) ^c 1.00 1.46 (1.35, 1.58) ^b 1.00
369 (82.1%) (4.7%) 07 (13.2%) 0.07) usight Score 39 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 0.167 (0.141, 0.193) ^c 1.00 1.46 (1.35, 1.58) ^b 1.00
(4.7%) (7 (13.2%) (0%) weight Score (39 (0.959) tal unit (224 (88.7%) (5 (10.6%) (0.7%) (0.7%) nin 709 (91.1%) 58 (8.1%)	572 (5.6%) 1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.23 (1.11, 1.37) 1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.22 (1.07, 1.40) ^b 1.21 (1.13, 1.29) ^b 0.167 (0.141, 0.193) ^c 1.00 1.46 (1.35, 1.58) ^b 1.00
07 (13.2%) 0.0%) weight Score 039 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	1,600 (15.5%) 3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.23 (1.15, 1.31) 0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	1.21 (1.13, 1.29) ^b 0.167 (0.141, 0.193) ^c 1.00 1.46 (1.35, 1.58) ^b 1.00
1.0%) weight Score 039 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	3 (0.0%) 0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	0.171 (0.145, 0.197) 1.00 1.43 (1.33, 1.53) 1.00	0.167 (0.141, 0.193)° 1.00 1.46 (1.35, 1.58) ^b 1.00
weight Score 139 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	0.132 (1.036) 8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00 1.43 (1.33, 1.53) 1.00	1.00 1.46 (1.35, 1.58) ^b 1.00
339 (0.959) tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00 1.43 (1.33, 1.53) 1.00	1.00 1.46 (1.35, 1.58) ^b 1.00
tal unit 224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	8,747 (85.0%) 1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00 1.43 (1.33, 1.53) 1.00	1.00 1.46 (1.35, 1.58) ^b 1.00
224 (88.7%) 75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.43 (1.33, 1.53) 1.00	1.46 (1.35, 1.58) ^b 1.00
75 (10.6%) (0.7%) nin 709 (91.1%) 58 (8.1%)	1,492 (14.5%) 52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.43 (1.33, 1.53) 1.00	1.46 (1.35, 1.58) ^b 1.00
(0.7%) nin 709 (91.1%) 58 (8.1%)	52 (0.5%) 9,350 (90.9%) 924 (9.0%)	1.00	1.00
nin 709 (91.1%) 58 (8.1%)	9,350 (90.9%) 924 (9.0%)		
709 (91.1%) 58 (8.1%)	924 (9.0%)		
58 (8.1%)	924 (9.0%)		
		1.12 (1.03, 1.21)	0.93 (0.83, 1.04) ^d
(0.0%)	17 (0.2%)		
(0.5%)	1, (0.270)		
nin			
065 (97.7%)	10,096 (98.1%)	1.00	1.00
(1.5%)	177 (1.7%)	0.86 (0.71, 1.04)	0.94 (0.72, 1.23) ^d
(0.9%)	18 (0.2%)		
ly males include	ed)		•
284 (98.7%)	5,314 (98.7%)	1.00	1.00
(1.3%)	70 (1.3%)	1.02 (0.76, 1.36)	1.05 (0.78, 1.42) ^b
ts		,	· · ·
527 (99.9%)	10,263 (99.7%)	1.00	1.00
(0.1%)	28 (0.3%)	3.29 (1.80, 6.02)	3.62 (1.95, 6.74) ^b
ects	. , ,		
514 (99.9%)	10,277 (99.9%)	1.00	1.00
(0.1%)			0.81 (0.41, 1.58) ^b
			, , ,
		1.00	1.00
			1.49 (1.09, 2.03) ^b
· -· · /	- \ /	- (,,	
538 (99,9%)	10,284 (99 9%)	1.00	1.00
1			2.93 (0.97, 8.88) ^b
1	. (0.1.))	2.00 (01/0) 0.04/	
ne*	10 097 (98 1%)	1.00	1.00
	10,007 (00.170)		1.38 (1.15, 1.67) ^b
	0.1%)	0.1%) 14 (0.1%) males included) 317 (99.0%) 5,308 (98.6%) (1.0%) 76 (1.4%) 538 (99.9%) 10,284 (99.9%) .1%) 7 (0.1%) ne* 258 (98.6%) 258 (98.6%) 10,097 (98.1%)	0.1% 14 (0.1%) 0.93 (0.49, 1.76) males included) 1.00 1.00 317 (99.0%) 5,308 (98.6%) 1.00 1 (1.0%) 76 (1.4%) 1.48 (1.09, 1.99) 538 (99.9%) 10,284 (99.9%) 1.00 .1%) 7 (0.1%) 2.33 (0.78, 6.94) me* 1

582

583 ^a Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, maternal


584 hypertensive disorders, maternal antepartum haemorrhage

585 ^b Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, gestation at 586 delivery

^c Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking 587

- ^d Adjusted for year of delivery, maternal age at delivery, SIMD, first gestational booking, type of 588
- 589 delivery
- *Including cryptorchidism, neural tube defects, amniotic band defects, hypospadias, gastroschisis 590

35




591

- Figure 1. Flowchart of cohort selection and sub-group analyses. n=number of 592
- pregnancies in each analysis.*98.3% of pregnancies using only diclofenac occurred 593
- during 2005-2015, therefore analysis was performed only on data from that decade 594
- to rule out any temporal effect. 595


36






598

Figure 2. Prevalence of use during pregnancy for each analgesic sub-group over our 599 30-year study period. In 2005 there was a change in legislation making diclofenac 600 available without prescription. 601



37



603

Figure S1. Directed acyclic graph (DAG) of exposure to outcome path and relevant 604

605 measured and unmeasured biasing factors in our analysis.